Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals
AMLX | NASDAQ
Chart Builder DCF Calculator
$27.80
-$2.49 (-8.22%)
At close: Nov 16, 2026, 4:00 PM ET
$27.67
-$0.13 (-0.47%)
After-hours: Nov 16, 2026, 7:30 PM ET

Amylyx Pharmaceuticals Company Profile

Company profile explained

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Key Executives

Name Position
Joshua Cohen Co-Founder, Co-CEO & Director
Justin Klee Co-CEO & Director
Gina Mazzariello Chief Legal Officer & General Counsel
James Frates Chief Financial Officer
Camille L. Bedrosian Chief Medical Officer
Linda A. Arsenault Chief Human Resources Officer
Lindsey Allen Head of Investor Relations & Communications
Machelle Manuel Vice President & Head of Global Medical Affairs
Tammy Sarnelli Global Head of Regulatory Affairs
Tom Holmes Chief Technical Operations Officer

Latest SEC Filings

Date Type Title
Oct 07, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 08, 2026 8-K Current Report
Sep 02, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 20, 2026 4 Filing
View All SEC Filings ➞
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals logo
Country United States
IPO Date Jan 7, 2022
Industry Biotechnology
Sector Healthcare
Employees 136
CEO Joshua Cohen

Contact Details

55 Cambridge Parkway Cambridge, Massachusetts 02142 United States

Stock Details

Ticker Symbol AMLX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001658551
CUSIP Number 03237H101
ISIN Number US03237H1014
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.